Home > Cardiology > ISTH 2020 > What’s New in Venous Thromboembolism > Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis

Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis

Presented By
Dr Florian Moik, Medical university of Vienna, Austria
Conference
ISTH 2020
Trial
Cohort study
A single-centre cohort study found a venous thromboembolism (VTE) incidence of over 10% in cancer patients treated with immune checkpoint inhibitors (ICI). VTE was further associated with an elevated mortality risk [1]. The retrospective study tried to fill the knowledge gap concerning potential increased thromboembolic risk for cancer patients who are treated with ICI. Dr Florian Moik (Medical university of Vienna, Austria) and colleagues explored the likelihood of arterial thromboembolism (ATE) and VTE in a cohort of 580 patients who were treated with ICI at the Medical University of Vienna between 2015 and 2018. They also carried out an assessment of risk factors as well as a possible clinical impact. The most common cancer diagnosis identified in the chart review was melanoma in 35.6% and non-small-cell lung cancer in 27.2% of the cases. Of the ICI-treated subjects, 89.1% were at stage 4 of their disease. Median age was 64 years, BMI 24.5, and 40.5% of...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on